Title (en)

COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER2/NEU

Title (de)

ZUSAMMENSETZUNGEN UND VERFAHREN FÜR TUMORIMPFUNG UND IMMUNTHERAPIE MIT HER2/NEU

Title (fr)

COMPOSITIONS ET PROCÉDÉS DE VACCINATION ET D'IMMUNOTHÉRAPIE TUMORALES IMPLIQUANT HER2/NEU

Publication

EP 3464560 A4 20200115 (EN)

Application

EP 17807584 A 20170602

Priority

- US 201662345575 P 20160603
- US 201662361292 P 20160712
- US 2017035718 W 20170602

Abstract (en)

[origin: WO2017210579A1] In certain embodiments, methods and compositions are provided for generating immune responses against tumor antigens such as a HER2/neu antigen or epitope. In particular embodiments there may be provided methods for constructing and producing recombinant adeno virus-based vector vaccines containing nucleic acid sequences encoding tumor antigens such as a HER2/neu antigen or epitope that allow for vaccinations in individuals with preexisting immunity to adenovirus.

IPC 8 full level

C12N 1/21 (2006.01); **A61K 39/00** (2006.01); **C07K 14/71** (2006.01); **C12N 1/19** (2006.01)

CPC (source: EP KR US)

A61K 38/2086 (2013.01 - KR); **A61K 39/001106** (2018.08 - EP KR US); **A61K 39/00117** (2018.08 - EP KR); **A61K 39/001182** (2018.08 - EP KR); **A61K 39/39541** (2013.01 - KR); **A61P 35/00** (2018.01 - KR); **A61P 35/04** (2018.01 - EP US); **C07K 14/71** (2013.01 - EP US); **C12N 15/85** (2013.01 - US); **C12N 15/86** (2013.01 - EP US); A61K 2039/5154 (2013.01 - EP KR); A61K 2039/5254 (2013.01 - EP KR US); A61K 2039/5256 (2013.01 - EP KR US); A61K 2039/585 (2013.01 - KR); C12N 2710/10343 (2013.01 - EP KR US)

Citation (search report)

- [X] WO 2006130525 A2 20061207 - SIDNEY KIMMEL CANCER CT [US], et al
- [XP] WO 2017075570 A1 20170504 - US HEALTH [US], et al
- [A] WO 2014031178 A1 20140227 - ETUBICS CORP [US], et al
- [XI] DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1 February 2016 (2016-02-01), LATCHMAN Y ET AL: "A novel combination HER2, brachyury, and MUC1 adenovirus based vaccines for a multitargeted immunotherapy approach to treat breast cancer", XP002795787, Database accession no. EMB-624570414 & LATCHMAN Y ET AL: "A novel combination HER2, brachyury, and MUC1 adenovirus based vaccines for a multitargeted immunotherapy approach to treat breast cancer", MOLECULAR CANCER RESEARCH 20160201 AMERICAN ASSOCIATION FOR CANCER RESEARCH INC. NLD, vol. 14, no. 2, Supplement, 1 February 2016 (2016-02-01), ISSN: 1557-3125
- [X] LUIGI AURISICCHIO ET AL: "Immunogenicity and Therapeutic Efficacy of a Dual-Component Genetic Cancer Vaccine Cotargeting Carcinoembryonic Antigen and HER2/ neu in Preclinical Models", HUMAN GENE THERAPY, vol. 25, no. 2, 1 February 2014 (2014-02-01), pages 121 - 131, XP055643329, ISSN: 1043-0342, DOI: 10.1089/hum.2013.103
- [X] HARTMAN ZACHARY C ET AL: "An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity", CLINICAL CANCER RESEARCH, vol. 16, no. 5, 1 March 2010 (2010-03-01), AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, pages 1466 - 1477, XP002777731, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-254
- [X] H-J KO ET AL: "Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys", GENE THERAPY, vol. 15, no. 20, 15 May 2008 (2008-05-15), GB, pages 1351 - 1360, XP055643340, ISSN: 0969-7128, DOI: 10.1038/gt.2008.81
- [A] E S GABITZSCH ET AL: "An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice", CANCER GENE THERAPY, vol. 18, no. 5, 1 May 2011 (2011-05-01), pages 326 - 335, XP055078706, ISSN: 0929-1903, DOI: 10.1038/cgt.2010.82
- See also references of WO 2017210579A1

Cited by

US10961310B2; US11739146B2; US11981715B2; US10676516B2; US11466068B2; US10946068B2; US11779632B2; US11091526B2; US11091527B2; US11945852B2; US11965008B2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2017210579 A1 20171207; **WO 2017210579 A8 20180125**; AU 2017273878 A1 20190103; CA 3026345 A1 20171207; CN 110234752 A 20190913; EP 3464560 A1 20190410; EP 3464560 A4 20200115; IL 263382 A 20181231; JP 2019521099 A 20190725; KR 20190034160 A 20190401; TW 201805013 A 20180216; US 2019134174 A1 20190509

DOCDB simple family (application)

US 2017035718 W 20170602; AU 2017273878 A 20170602; CA 3026345 A 20170602; CN 201780046622 A 20170602; EP 17807584 A 20170602; IL 26338218 A 20181129; JP 2018563469 A 20170602; KR 20187037611 A 20170602; TW 106118354 A 20170602; US 201716306088 A 20170602